SYR 619

Drug Profile

SYR 619

Alternative Names: SYR619

Latest Information Update: 15 May 2007

Price : $50

At a glance

  • Originator Takeda San Diego
  • Class Antihyperglycaemics
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 11 May 2007 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 25 Jul 2005 Takeda and PPD have entered into an agreement providing Takeda with the development and marketing rigths to all DPP IV inhibitors that were previouslly granted to PPD by Syrrx (now Takeda San Diego)
  • 01 Mar 2005 Syrrx has been acquired by Takeda and renamed Takeda San Diego
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top